IL6 and COVID-19: A double-blinded randomized controlled trial demonstrated that Xuebijing injection may suppress the cytokine storm and prevent the progression to ARDS in severe COVID-19 patients by regulating the secretion of pro-inflammatory cytokine IL-6, IL-8, and TNF-α (Luo et al., 2021).